Kevin P. Danahy serves as the Chief Executive Officer at Pulse Biosciences Inc., a company focused on developing novel therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. With a strong background in the medical technology industry, Danahy has been instrumental in guiding Pulse Biosciences through the development and commercialization of its innovative treatments. His leadership has been pivotal in advancing the company's mission to improve patient outcomes through cutting-edge technology. Before joining Pulse Biosciences, Danahy held various executive positions in the healthcare sector, where he demonstrated a keen ability to drive growth and innovation. His experience includes roles at companies such as Stryker and Boston Scientific, where he honed his skills in strategic planning, product development, and market expansion. At Pulse Biosciences, Danahy has leveraged this expertise to steer the company towards significant milestones, including the successful completion of clinical trials and the pursuit of regulatory approvals for new applications of NPS technology. Under Danahy's leadership, Pulse Biosciences has made notable strides in the field of medical technology, particularly in the areas of dermatology and oncology. His vision for the company includes expanding the reach of NPS technology to address unmet medical needs and improve the quality of life for patients worldwide. Danahy's strategic approach and dedication to innovation continue to position Pulse Biosciences as a leader in the development of novel therapeutic solutions.